Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Voyager Lifts Off With $45M From Third Rock Ventures

This article was originally published in The Pink Sheet Daily

Executive Summary

The venture firm’s latest incubated project is a gene therapy start-up targeting CNS disorders. Voyager hopes to have three programs in the clinic by early 2017, targeting Parkinson’s, ALS and Friedreich’s ataxia.

You may also be interested in...



AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics

Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.

Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio

Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel